Oligopolies and Monopolistic Competition - Grifols/Talecris Merger
Unit 5 – GROUP PROJECT
Oligopolies and Monopolistic Competition - Grifols/Talecris Merger
Rhonda D. Smith-Payne
AIU Online
Contributing Group Members: Rhonda D. Smith-Payne
Non-Contributing Group Members: Ashley Battle, Latonia Jenkins, Betty Johnson, Crystal Williams
Abstract
The purpose of this report is to assess the impact of mergers on industry, on consumers, and on society as a whole and more specifically, the Grifols/Talecris Merger in the plasma-derived pharmaceutical industry. A complete description of the industry is discussed in depth. Part II discusses arguments in support of the merger and opposing the merger. Grifols purchased Talecris in 2009, creating a merger which did not come without strict opposition. Supporting references assist in discussing Federal Trade Commission case against the Grifols/Talecris merger. In regards to remaining cited material, references are provided. A footnote concludes this report, explaining the circumstances related to this project.
UNIT 5 - OLIGOPOLIES AND MONOPOLISTIC COMPETITION - GRIFOLS/TALECRIS MERGER
Part I
After reviewing The Federal Trade Commission’s website at http://www.ftc.gov/bc/index.shtml and selecting one proposed merger industry; this report will discuss the Grifols/Talecris merger.
Grifols, S.A is a manufacturer of plasma-derived drugs. Headquartered in Barcelona, Spain, the company develops and manufactures human blood plasma-derived products, with facilities in Barcelona and Los Angeles. “Grifols entered the U.S. market in 2002, when it acquired the assets of a U.S. manufacturer, Alpha Therapeutics Corporation, and 42 plasma collection centers from SeraCare. Since then, Grifols has acquired additional plasma centers and is now vertically integrated, making it the second largest plasma collector in the world. Grifols employs approximately 6,000 people worldwide and had global 2009 revenues of $1.3 billion.” (Commission, 2011)
Talecris Biotherapeutics Holdings
Oligopolies and Monopolistic Competition - Grifols/Talecris Merger
Rhonda D. Smith-Payne
AIU Online
Contributing Group Members: Rhonda D. Smith-Payne
Non-Contributing Group Members: Ashley Battle, Latonia Jenkins, Betty Johnson, Crystal Williams
Abstract
The purpose of this report is to assess the impact of mergers on industry, on consumers, and on society as a whole and more specifically, the Grifols/Talecris Merger in the plasma-derived pharmaceutical industry. A complete description of the industry is discussed in depth. Part II discusses arguments in support of the merger and opposing the merger. Grifols purchased Talecris in 2009, creating a merger which did not come without strict opposition. Supporting references assist in discussing Federal Trade Commission case against the Grifols/Talecris merger. In regards to remaining cited material, references are provided. A footnote concludes this report, explaining the circumstances related to this project.
UNIT 5 - OLIGOPOLIES AND MONOPOLISTIC COMPETITION - GRIFOLS/TALECRIS MERGER
Part I
After reviewing The Federal Trade Commission’s website at http://www.ftc.gov/bc/index.shtml and selecting one proposed merger industry; this report will discuss the Grifols/Talecris merger.
Grifols, S.A is a manufacturer of plasma-derived drugs. Headquartered in Barcelona, Spain, the company develops and manufactures human blood plasma-derived products, with facilities in Barcelona and Los Angeles. “Grifols entered the U.S. market in 2002, when it acquired the assets of a U.S. manufacturer, Alpha Therapeutics Corporation, and 42 plasma collection centers from SeraCare. Since then, Grifols has acquired additional plasma centers and is now vertically integrated, making it the second largest plasma collector in the world. Grifols employs approximately 6,000 people worldwide and had global 2009 revenues of $1.3 billion.” (Commission, 2011)
Talecris Biotherapeutics Holdings
References: In The Matter of Grifolis/Talecris - press release. (2011, JUN 1). Retrieved OCT 29, 2011, from www.ftc.gov: http://www.ftc.gov In the Matter of Grifols, S.A. and Talecris Biotherapeutics Holdings Corp., File No. 101-0153 (Federal Trade Comission JUN 6, 2011). UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION, Docket No. C-4322 1010153 (Federal Trade Commission MAY 31, 2011). UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION, Docket No. C-4322 (THE FEDERAL TRADE COMMISSION Jun 6, 2011). Berman, K. E. (2011, JAN nd). international blood/plasma news. Retrieved NOV 6, 2011, from marketingresearchbureau.com: http://www.marketingresearchbureau.com/IBPN_Jan_2011.pdf Chhabra, T. (2010, DEC 12). Listing of Biotech Companies. Retrieved NOV 6, 2011, from eHowMoney: http://www.ehow.com/list_7487094_listing-biotech-companies.html Comission, F. T. (2011, JUN 1). FTC Challenges Grifolis/Talecris Merger. Retrieved OCT 29, 2011, from www.ftc.gov: http://www.ftc.gov/opa/2011/06/grifols.shtm Commission, F. T. (2011). ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS Orders To Aid Public Comment.pdf. Washington, D.C.: Federal Trade Commission. Visiongain. (2009, JAN nd). Top 10 Biotech Companies. Retrieved NOV 6, 2011, from Pharmaceutical Market Research: http://www.pharmaceutical-market-research.com/publications/biotechnology/company_reports/top_10_biotech_companies.html Group Assignment Footnote: This assignment is a Group Project for Microeconomics AIUOnline - Unit 5 - Oligopolies and Monopolistic Competition - Grifols/Talecris Merger. The group originally consisted of 5 members, assigned by the Instructor. Throughout the course of the group project and for the compilation of this report, the author of this report was abandoned by the remaining group members. The suggestions, research, writings, and compilation of all material contained in this report are the work of one individual, rather than five, as assigned.